AbbVie (NYSE:ABBV) Releases Q2 2026 Earnings Guidance

AbbVie (NYSE:ABBV) issued an update on its second quarter 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 3.570-3.610 for the period, compared to the consensus EPS estimate of 3.770. The company issued revenue guidance of -. AbbVie also updated its FY 2026 guidance to 13.910-14.110 EPS.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Morgan Stanley raised their target price on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Evercore set a $235.00 price objective on AbbVie in a research note on Friday, May 15th. Guggenheim restated a “buy” rating and issued a $249.00 price objective on shares of AbbVie in a report on Friday, May 1st. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $298.00 target price on shares of AbbVie in a report on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $256.67.

AbbVie Price Performance

Shares of AbbVie stock opened at $252.98 on Thursday. The stock’s 50 day simple moving average is $223.50 and its 200-day simple moving average is $220.90. The stock has a market cap of $446.96 billion, a P/E ratio of 124.62, a P/E/G ratio of 0.84 and a beta of 0.30. AbbVie has a 1-year low of $184.63 and a 1-year high of $261.64.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.46 earnings per share. As a group, research analysts expect that AbbVie will post 14.19 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Wednesday, July 15th. AbbVie’s payout ratio is currently 340.89%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved AbbVie’s Tepkinly in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, expanding the drug’s commercial opportunity in Europe and reinforcing AbbVie’s oncology growth pipeline. EC approves AbbVie’s Tepkinly combination for follicular lymphoma
• Positive Sentiment: AbbVie completed a first-in-human study for ABBV-277, a clinical-stage program that could provide additional safety and efficacy data for investors watching the company’s next wave of pipeline assets. AbbVie’s ABBV‑277 Trial Completion: What Early Safety Data Could Mean for Investors
• Neutral Sentiment: AbbVie’s upcoming second-quarter earnings report is expected to show double-digit EPS growth, but investors are focused on whether results can offset recent concerns around forward guidance and margin trends. AbbVie Earnings Preview: What to Expect
• Negative Sentiment: AbbVie lowered its FY 2026 EPS guidance to $13.91-$14.11, below the consensus estimate of $14.25, and also guided Q2 EPS to $3.57-$3.61 versus expectations of $3.77, which is likely weighing on the shares today.

Institutional Investors Weigh In On AbbVie

Several hedge funds and other institutional investors have recently bought and sold shares of ABBV. T. Rowe Price Investment Management Inc. grew its position in AbbVie by 38.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 25,847 shares of the company’s stock worth $5,906,000 after acquiring an additional 7,116 shares during the period. Strive Financial Group LLC purchased a new stake in AbbVie in the fourth quarter valued at $216,000. Blue Sparrow LLC DE acquired a new position in shares of AbbVie in the 4th quarter valued at $28,561,000. Mercer Global Advisors Inc. ADV lifted its stake in shares of AbbVie by 5.9% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 430,631 shares of the company’s stock valued at $100,411,000 after purchasing an additional 23,859 shares during the last quarter. Finally, Summit Global Investments grew its holdings in shares of AbbVie by 21.4% during the 4th quarter. Summit Global Investments now owns 16,916 shares of the company’s stock worth $3,865,000 after purchasing an additional 2,987 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.